|
Dr. Orloff is the Medical Director at Medpace, Inc., a contract research organization based in Cincinnati, Ohio, with a focus in the metabolism/diabetes/cardiovascular disease area. From 2000-2006, he was the Director of the Division of Metabolism and Endocrinology Products at the U.S. Food and Drug Administration (FDA). Dr. Orloff attended Harvard College and the New York University School of Medicine, graduating in 1984. After internship and residency in internal medicine at the Yale-New Haven Hospital, Dr. Orloff was a research and clinical fellow at the National Institutes of Health (NIH) from 1987-1994 where his work focused on signal transduction and translational control of gene expression. In addition while at NIH, he completed a clinical endocrinology fellowship in the joint NICHD-NIDDK program.
In 1994, Dr. Orloff moved to FDA where he was in charge of FDA’s regulatory oversight of new drugs for the treatment of dyslipidemia, diabetes, obesity, osteoporosis, thyroid disease, growth disorders, and inborn errors of metabolism, in addition to the panoply of other indications in endocrinology and metabolic disease.
Dr. Orloff’s clinical work at NIH over the past many years has been in dyslipidemia and cardiovascular disease prevention. He was a consultant to the National Cholesterol Education Program’s Adult Treatment Panel III. Until leaving federal service, Dr. Orloff was a commissioned officer (Capt., 0-6) in the U.S. Public Health Service (PHS), and he is the recipient of multiple honors, including the PHS Outstanding Service Medal. He serves on the board of directors of the Foundation for Advanced Education in the Sciences at NIH. He has published in both the basic sciences and in recent years on clinical trial and regulatory issues in drug development and approval. | 